Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
2018 in accordance with PRISMA guidelines to report biomarkers with respect to their application in PCa diagnosis, progression, aggressiveness, recurrence, and treatment response. The vast majority of studies report biomarkers with the ability to distinguish malignant from benign prostate tissue with a few studies investigating biomarkers associated with disease progression, treatment response or tumour recurrence. In general, these studies report high dimensional datasets and the number (...) Metabolomics Biomarkers of ProstateCancer: A Systematic Review. Prostatecancer (PCa) diagnosis with current biomarkers is difficult and often results in unnecessary invasive procedures as well as over-diagnosis and over-treatment, highlighting the need for novel biomarkers. The aim of this review is to provide a summary of available metabolomics PCa biomarkers, particularly for clinically significant disease. A systematic search was conducted on PubMed for publications from July 2008 to July
Aspirin Exposure and Mortality Risk among ProstateCancer Patients: A Systematic Review and Meta-Analysis. Prostatecancer (PCa) is the ninth most common cause of cancer death globally. Many studies have investigated aspirin exposure and mortality risk among PCa patients, returning inconsistent results. We conducted a comprehensive meta-analysis to explore the association between aspirin exposure and mortality risk among PCa patients and to investigate potential dose/duration/frequency-response (...) relationships.Studies published from 1980 to 2018 of PubMed and EMBASE databases were searched. We included 14 studies with 110,000 participants. Multivariate-adjusted odds ratios (ORs) were pooled using random-effect models. Potential dose/duration/frequency-response relationships were evaluated for aspirin exposure and prostatecancer-specific mortality (PCSM) risk. We did not detect an association between the highest aspirin exposure and mortality risk (PCSM of prediagnostic aspirin exposure, OR: 0.96, 95
High prevalence of secondary bladder cancer in men on radiotherapy for prostatecancer: evidence from a meta-analysis. To assess whether radiotherapy (RT) for prostatecancer (PCa) was a risk factor for secondary bladder cancer (BLCa) through a meta-analysis.The MEDLINE, Embase, and the Cochrane Library were systematically searched for all studies investigating the risk of BLCa in patients with RT. The association between RT and risk of BLCa was summarized using hazard ratio with a 95%CI
The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With ProstateCancer: A Systematic Review and Meta-Analysis. Background: Programmed cell death ligand 1 (PD-L1) expression has been shown to correlate with poor prognosis in diverse human cancers. However, limited data exist on the prognostic and clinicopathologic significance of PD-L1 expression in prostatecancers (PCa), and the curative effect of anti-PD-1/PD-L1 therapy remains
Focal Neuroendocrine Differentiation of Conventional ProstateAdenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis. The biologic and prognostic value of focal neuroendocrine differentiation (NED) in conventional prostateadenocarcinoma (PC) patients who undergo radical prostatectomy (RP) remains controversial. In this systematic review and meta-analysis, we assessed the association of focal NED in conventional PC with oncological outcomes (...) after RP. A literature search using PubMed, Scopus, Web of Science, and Cochrane Library was conducted on December 2018 to find relevant studies according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. We used a fixed-effect model to analyze the impact of focal NED in RP specimen on progression-free survival defined by biochemical recurrence (BCR). A total of 16 studies with the outcomes of disease progression and survival were eligible. No patient
Chromogranin A is a predictor of prognosis in patients with prostatecancer: a systematic review and meta-analysis. Background: The prognostic value of chromogranin-A (CHGA) as a biomarker of prostatecancer (PCa) has been evaluated extensively. However, to date the results still remain controversial. This study aims to perform a meta-analysis on previous studies in order to determine whether CHGA would be a biomarker for survival in PCa patients. Methods: MEDLINE, Embase, Web of Science
Apparent diffusion coefficient in extraprostatic extension of prostatecancer: a systematic review and diagnostic meta-analysis. Objective: To evaluate the diagnostic performance of apparent diffusion coefficient (ADC) for local staging of prostatecancer. Methods: Databases of Web of Science, MEDLINE (Ovid and PubMed), Cochrane Library, EMBASE, and Google Scholar were searched up to May 31, 2018, with language restricted to English. All studies concerning multiparametric magnet resonance
Transperineal versus transrectal prostate biopsy in the diagnosis of prostatecancer: a systematic review and meta-analysis. Because conventional prostate biopsy has some limitations, optimal variations of prostate biopsy strategies have emerged to improve the diagnosis rate of prostatecancer. We conducted the systematic review to compare the diagnosis rate and complications of transperineal versus transrectal prostate biopsy. We searched for online publications published through June 27, 2018 (...) be identified.To conclude, this review indicated that transperineal and transrectal prostate biopsy have the same diagnosis accuracy, but the transperineal approach has a lower risk of fever and rectal bleeding. More studies are warranted to confirm these findings and discover a more effective diagnosis method for prostatecancer.
Letter to the editor regarding the publication "Association between matrix-metalloproteinase polymorphisms and prostatecancer risk: a meta-analysis and systematic review". 30774434 2020 02 25 1179-1322 11 2019 Cancer management and research Cancer Manag Res Letter to the editor regarding the publication "Association between matrix-metalloproteinase polymorphisms and prostatecancer risk: a meta-analysis and systematic review". 1067-1068 10.2147/CMAR.S195169 Jayaraj Rama R Clinical Sciences (...) , College of Health and Human Sciences, Charles Darwin University, Casuarina, NT, Australia, email@example.com. Kumarasamy Chellan C University of Adelaide, Adelaide, SA, Australia. eng Journal Article Comment 2019 01 24 New Zealand Cancer Manag Res 101512700 1179-1322 Cancer Manag Res. 2018 Nov 02;10:5247-5259 30464622 Disclosure The authors report no conflicts of interest in this communication. 2019 2 19 6 0 2019 2 19 6 0 2019 2 19 6 1 epublish 30774434 10.2147/CMAR.S195169 cmar-11-1067
Moderate hypofractionated radiotherapy vs conventional fractionated radiotherapy in localized prostatecancer: a systemic review and meta-analysis from Phase III randomized trials. To determine the efficacy and late toxicities of moderate (2.5-4 Gy) hypofractionated radiotherapy (H-RT) in localized prostatecancer, a meta-analysis of published randomized clinical trials comparing moderate H-RT with conventional fractionated RT (C-RT) was performed.Systematic search on published randomized (...) clinical trials in English according to Cochrane review guidelines in databases of Pubmed, Embase, Cochrane, web of science, and Wiley Online Library was carried out. Outcomes of interests were biochemical and clinical disease failure (BCDF), biochemical failure (BF), overall survival (OS), and late toxicities.Seven of the 365 studies fulfilled inclusion criteria with 8,156 participants. Compared with C-RT, moderate H-RT showed a lower BF rate (risk ratio [RR] =0.80, 95% CI: 0.68-0.95, P=0.009), while
Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostatecancer: a meta-analysis. Pretreatment inflammatory factors, including neutrophil, lymphocyte, platelet and monocyte counts as well as the ratios between them such as neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and lymphocyte-monocyte ratio (LMR) have been suggested as potential prognostic predictors for patients with prostatecancer (PCa). However, the prognostic (...) effects remain controversial. Therefore, the goal of this study was evaluate the prognostic values of these markers for PCa patients using a meta-analysis.Potentially relevant publications in PubMed and Cochrane Library were searched. Pooled hazard ratio (HR) with 95% confidence interval (CI) for overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), recurrence free survival (RFS) and distant metastases-free survival (DMFS) were determined using a fixed or random
with quantitative results by residential rurality and/or disadvantage. Studies were critically appraised using a modified Newcastle-Ottawa Scale. Results: Overall 169 studies met the inclusion criteria. Around 50% were assessed as high quality and 50% moderate. Men from disadvantaged areas had consistently lower prostate-specific antigen (PSA) testing and prostatecancer incidence, poorer survival, more advanced disease and a trend toward higher mortality. Although less consistent, predominant patterns (...) by rurality were lower PSA testing, prostatecancer incidence and survival, but higher stage disease and mortality among rural men. Both geographical measures were associated with variations in access and use of prostatecancer-related services for low to high risk disease. Conclusions: This review found substantial evidence that prostatecancer indicators varied by residential location across diverse populations and geographies. While wide variations in study design limited comparisons across studies
Can Lycopene Impact the Androgen Axis in ProstateCancer?: A Systematic Review of Cell Culture and Animal Studies. First-line therapy for advanced or metastatic prostatecancer (PCa) involves the removal of tumor-promoting androgens by androgen deprivation therapy (ADT), resulting in transient tumor regression. Recurrent disease is attributed to tumor adaptation to survive, despite lower circulating androgen concentrations, making the blockage of downstream androgen signaling a chemotherapeutic (...) goal for PCa. Dietary intake of tomato and its predominant carotenoid, lycopene, reduce the risk for PCa, and preclinical studies have shown promising results that tomato and lycopene can inhibit androgen signaling in normal prostate tissue. The goal of this systematic review was to evaluate whether mechanistic evidence exists to support the hypothesis that tomato or lycopene interact with the androgen axis in PCa. Eighteen studies (n = 5 in vivo; n = 13 in vitro) were included in the final review
Systemic Treatment for Metastatic Hormone Sensitive ProstateCancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. Several systemic treatments are available for metastatic hormone sensitive prostatecancer (mHSPC) including docetaxel (D), abiraterone and prednisone (A + P) and new anti-androgens (NA). In our study we performed a systematic review and meta-analysis assessing efficacy outcomes (survival and radiological-free survival), safety
Comparison of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy With Systematic Biopsy Alone for the Diagnosis of ProstateCancer: A Systematic Review and Meta-analysis. The current diagnostic pathway for patients with suspected prostatecancer (PCa) includes prostate biopsy. A large proportion of individuals who undergo biopsy have either no PCa or low-risk disease that does not require treatment. Unnecessary biopsies may potentially be avoided with prebiopsy imaging.To compare (...) the performance of systematic transrectal ultrasonography-guided prostate biopsy vs prebiopsy biparametric or multiparametric magnetic resonance imaging (MRI) followed by targeted biopsy with or without systematic biopsy.MEDLINE, Embase, Cochrane, Web of Science, clinical trial registries, and reference lists of recent reviews were searched through December 2018 for randomized clinical trials using the terms "prostatecancer" and "MRI."Randomized clinical trials comparing diagnostic pathways including
Corrigendum: Supervised Physical Training Enhances Muscle Strength but Not Muscle Mass in ProstateCancer Patients Undergoing Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. [This corrects the article DOI: 10.3389/fphys.2019.00843.].
Photodynamic therapy for prostatecancer: a systematic review and meta-analysis. Photodynamic therapy (PDT) is an emerging focal treatment modality for prostatecancer. However, the efficacy, safety, and functional outcomes of PDT are not clear. We performed a meta-analysis of available single-arm studies and control trials which used PDT for prostate cancer.We searched Pubmed, Embase, Ovid and the Cochrane library (until March,2018) for studies about PDT in patients with prostatecancer (...) with decreasing rate of 29.1% (95.0 % CI: 2.7%-55.5%, I2 = 96.9%). Five of the included studies evaluated IIEF-5 with decreasing rate of 14.9% (95.0% CI: 6.8%-23.0%, I2 = 44.2%). The most common adverse events were haematuria (28.1%, 95.0% CI: 17.1%-39.2%, I2 = 79.8%), erectile dysfunction (23.1%, 95.0% CI: 9.7%-36.5%, I2 = 87.7%), and dysuria (18.6%, 95.0% CI: 12.1%-25.0 %, I2 = 53.4 %).The meta-analysis results shows that PDT for patients with prostatecancer can be considered as effective based on single
Erratum: A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostatecancer: Erratum. [This corrects the article DOI: 10.1097/MD.0000000000003845.].
Health-related Quality of Life in Patients with Advanced ProstateCancer: A Systematic Review. The assessment of "soft" endpoints such as health-related quality of life (HRQOL) is increasingly relevant when evaluating the optimal treatment sequence of novel therapeutic options in patients with advanced prostatecancer (PCa).To systematically review contemporary data regarding HRQOL outcomes in patients with advanced PCa.A systematic review of the literature published between January 2011 (...) and March 2019 was performed using the PubMed/Medline Database. In total, 873 articles were screened, and 14 articles including 12 661 patients were selected for synthesis and included in the current analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) and European Association of Urology recommendations.Regarding HRQOL assessment, the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire was used in 11 of 14 studies, the European Quality
Real-Time Elastography in the diagnosis of prostatecancer: a systematic review. To evaluate the diagnostic accuracy of real-time elastography as a method for detecting prostate cancer.Relevant studies applying real-time elastography as the diagnostic modality and biopsy as the reference standard, published by March 1, 2018 were retrieved from PubMed, EMBASE, Web of Science and Cochrane Library databases. Two independent reviewers inspected all these articles to confirm the matching (...) modality for the non-invasive diagnosis of patients with prostatecancer. The diagnostic accuracy of real-time elastography correlates tightly to the presence of higher PSA level and may help avoid unnecessary biopsy. It seems to be a useful tool in systemic biopsy.